TWI230611B - Anti-infection composition and food containing such anti-infection composition - Google Patents
Anti-infection composition and food containing such anti-infection composition Download PDFInfo
- Publication number
- TWI230611B TWI230611B TW091110088A TW91110088A TWI230611B TW I230611 B TWI230611 B TW I230611B TW 091110088 A TW091110088 A TW 091110088A TW 91110088 A TW91110088 A TW 91110088A TW I230611 B TWI230611 B TW I230611B
- Authority
- TW
- Taiwan
- Prior art keywords
- infection
- composition
- lactic acid
- heat
- acid bacteria
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 title claims abstract description 13
- 230000002924 anti-infective effect Effects 0.000 title abstract 4
- 241000894006 Bacteria Species 0.000 claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 21
- 241001327634 Agaricus blazei Species 0.000 claims abstract description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 28
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 239000004310 lactic acid Substances 0.000 claims description 14
- 235000014655 lactic acid Nutrition 0.000 claims description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 230000037406 food intake Effects 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 abstract description 8
- 241000194032 Enterococcus faecalis Species 0.000 abstract description 3
- 229940032049 enterococcus faecalis Drugs 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 238000012360 testing method Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- 241000186781 Listeria Species 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000002689 soil Substances 0.000 description 8
- 102000013462 Interleukin-12 Human genes 0.000 description 7
- 108010065805 Interleukin-12 Proteins 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 241000222350 Pleurotus Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000194036 Lactococcus Species 0.000 description 4
- 241000186779 Listeria monocytogenes Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 4
- 235000011613 Pinus brutia Nutrition 0.000 description 4
- 241000018646 Pinus brutia Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000121220 Tricholoma matsutake Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 235000011869 dried fruits Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- LLIANSAISVOLHR-GBCQHVBFSA-N 5-[(3as,4s,6ar)-2-oxidanylidene-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LLIANSAISVOLHR-GBCQHVBFSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241001106597 Enterococcus lactis Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 235000000434 Melocanna baccifera Nutrition 0.000 description 1
- 241001497770 Melocanna baccifera Species 0.000 description 1
- 241000828418 Neomicrococcus lactis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 244000012838 Phyllodium elegans Species 0.000 description 1
- 241000221662 Sclerotinia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000005338 frosted glass Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 108700027921 interferon tau Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Description
1230611 五、發明說明(1) 【發明之技術領域】 本發明係有關含有松簟屬·布萊傑·目利之k , 、 爻抽出物及 乳酸菌之加熱處理菌體作為有效成分之感染抑制組成物 含有該組成物之飲食品。 【發明之技術背景】 已知擔子菌綱ha ladake科之菇之松蕈屬·希常- • 唧來傑•目 利(Agaricus blazei Murill、日本名 川理哈、幸 」)為 具有可預防·改善癌症、過敏、糖尿病、高血壓等效果 成分,例如有關抗腫瘍活性成分,各自從該子實體^ 酸性多糖體(日本特開昭64- 6 71 94號公報)、中性多ϋ (曰本特開昭64-67195號公報)及蛋白多糖體(日士 # ^ β本特開平 2-78630號公報),從菌絲體分劃出蛋白多糖體f α丄 τ V日本特開 昭6 1 - 4 7 5 1 8號公報)、尤其是從菌絲體之培養溏 民/恩液分割出 蛋白多糖體(日本特開昭平61-47519號公報)。 一 松蕈屬·布萊傑·目利被廣泛利用於健康。 例如於特開2 0 0 1 -1 03927號公報揭示配合有將松葦 τ 在加壓下用水性溶劑抽出,將該抽出物用5 〇 % 磨兹 ^ ¢,1 獲得之松蕈屬蘑菇抽取物之食用組成物。 ▲ 於日本特開20 0 1 _17130號公報揭示有以於松 煎液中混合有醋及蜂蜜為特徵之含有松蕈屬 品。 1更康飲料食 於日本特開平1 1 -32 723號公報揭示有將松堇 之鹵4體、子實體及該混合物或該等之培養殘液 維素酶為主體之酵素劑進行分解處理,此時 、 J α侵件之含有
1230611 五、發明說明(2) 多量β -葡聚糖之生理活性物質作為主材料之健康食品。 又,自古以來乳酸菌亦作為健康食品廣泛被攝取,已 知除了具有改善腸内菌叢之平衡、減低腸内腐敗產物、改 善糞便性狀之效果之外還具有免疫賦活效果。例如於特開 〇1 48796號公報揭示有以乳酸球菌ADl〇l(Enterococcus faecalis AD101)菌株之死菌體作為主成分之免疫調整 劑0 =曰本特開平丨0_29946號公報揭示有以乳酸菌或該處 降低ϊ i有效成分之具有回復因藥劑所引起液性免疫機能 -之作用之液性免疫回復劑。 於曰本特開平6_805 75號公報揭 广或菌體含有物作為有效成分為特=== 體之公報揭示有以含有乳酸菌菌 活組成物“及/或細胞質劃分含有物為特徵之免疫賦 【發明解決課題】 利用品松丄π:自”或乳…然廣泛 生理效果者。 早獨攝取時能充分滿足 所以^ 交 制病# i t明之目的為提供經口攝$ , ¥ ϋ μ t # ㈣感染效果之感染抑制 ^優越之抑 飲令。 物及含有該組成物之 【解决課題之方法】
1230611 五、發明說明(4) 之抽出物及乳酸菌之加熱處理菌體作為有效成分 f ’攝取該等、组成物可期待優越之預防病5菌=安 ’、。又,於飲食品中添加本發明之减毕抑杳丨。感染 可提供預防病原菌等感染之飲食品。之感木抑制組成物, 本發明感染抑制組成物之抑制感 今尚不明瞭。認為是經由將松蕈屬·布' 用機序至 體及/或菌絲體培養物之抽出:目利之子實 併用攝取,可使以E % έ田胎=及礼酸菌之加熱處理菌體 胞性免产機谨Li ΝΚ細胞及7細胞為中心之Γ 【發明之實施形態】 ,、有效率地進行。 本發明感染抑制組成物有八 :·目利之子實體抽出物可 ;蕈屬.布萊 實體原物或是由將該經乾燥 2,·目利之子 出獲得。具體而言,可由蔣p乾鹿物用水、乙醇等溶劑抽 鐘,將所獲得之抽出液 7於120C抽出30分 又,松輩屬.ίίϊ Hi濃縮、乾燥獲得。 由將松蕈屬·布萊傑·目' 利,絲體培養物之抽出物可 養基培養,將獲得之之種菌用含有碳源及氮源之培 之操作、抽出獲得。、5經乾燥之菌體經由與上述相同 本發明中,松蕈屬 布μ 絲體培養物之抽出物亦可使隹目利之子實體及/或菌 本發明感染抑制組成物二=品。 處理菌體為將乳酸菌體經由之乳酸菌之加熱 m處理所獲得之死菌體,可
313641.ptd 1230611 五、發明說明(5) 由下述之方法獲得。 乳酸菌可由在樂果撒培養基,於30至45 °C培養12至72 小時後,經由離心分離等適當之方法將菌體回收。將所回 收之菌體水洗、濃縮,將該濃縮菌體懸濁液於8 〇至1 1 5 °C 加熱處理30分鐘至3秒鐘後經由喷霧乾燥、凍結乾燥等適 當方法乾燥獲得。上述之乳酸菌可列舉乳酸球菌 (Enterococcus faecalis)、乳酸腸球菌(Enterococcus faecium)、嗜乳酸桿菌(Lactobacillus acidophilus)、 乾酪乳桿菌(Lactobacillus casei)、乳酸乳桿菌 (Lactobacillus lactis)、瑞士 乳桿菌(Lactobacillus herveticus)、長雙岐桿菌(Bifidobacterium Longum)、 短雙岐桿菌(Bifidobacterium breve)、嗜熱性鏈球菌 (Streptococcus thermophilus)等°本發明中又以使用具 有更強力免疫賦活活性之乳酸腸球菌(E n t e r 〇 c 〇 c c u s faecalis)(ATCC 1 9433、ATCC 1 450 8、ATCC23655)特別理 想。乳酸球菌之加熱處理菌體亦可使用市售之例如「EF巴 瓦」、「EF- 2 00 1」(二者均為商品名,控必(股)公司製 造)、「FK-23」(商品名,曰曰製藥公司製造)。 本發明之感染抑制組成物以含有上述松蕈屬·布萊 傑·目利之子實體及/或菌絲體培養物之抽出物〇. 5至9 9. 5 質量%、上述乳酸菌之加熱處理菌體99.5至0·5質量%較 理想。又以含有松葦屬·布萊傑·目利之子實體及/或菌 絲體培養物之抽出物含有10至90質量%、上述乳酸菌之加 熱處理菌體90至10質量%更理想。各有效成分若在上述範
313641.ptd 第9頁 1230611 五、發明說明(7) 中,調製試驗液(250¾克/毫升)。 料,實驗MR庫存品」、曰本農業工業(股)公司製 投予後母曰觀察一次(觀察期為1 4曰),任何一群都 死亡例。觀察期結束時將所有之老鼠解剖檢查時主要 未發現異常。又,於投予後第7日、第1 4日測定體 經由t-檢定,以有意義水準5%進行群間之比較。妹 表1所示。 Q 1】 將4週歲之ICR系老鼠(雄雌各2〇隻,購自日本艾斯— 滋(股)公司)進行預備飼育約1週後分成試驗群(雄二各^ 隻)及對照群(雄雌各10隻),於試驗群,將上述試驗液以 乳酸球菌之加熱處理菌體換算為5,0 0 0毫克/公斤體重用田 管強制單次經口投予。於對照群,將精製水(雄·· 〇 · 7毫月 升、雌· 0 · 6毫升)以同樣之'方法投予,於將室溫設定為 土 2 °C、照明時間設定為1 2小時/日之飼育室飼育。又,、 試驗期間自由攝取水及飼料(商品名「老鼠、小老鼠用㈤; 形J 造) MTV if
看臟重果L
------ ---(公克) 〜 投 予前 投土後7日 投予後14日 — 雄 雌 雄 雌 雄 雌〜 對照群 30.7+ 1.2 26.7土 1.5 34.9± 1.4 29.2± 1.9 37.3± 1.9 31.0± l.f 群 3〇.7± 1.3 27.0± 1.4 35.5+ 2.0 -—---- 29,2± 1·7 38.3土 2.7 31.3+ 1.9^ 1230611 五、發明說明(8) 從表1 ’各群間雄 、 結果認為於乳酸球菌加重之增加並…差異。由以上之 之LD5G在5, 〇〇〇毫八:處理菌體之老鼠,單次經口投予 笔克’公斤體重以上。 將7週歲之Β Α丨R ι 公司)分成4群(每群各?〇隻雌二(:二曰本克雷亞(股) 制經口於試驗群投予γ ),用月s母群母日1次各自強 物(乾燥子實體0_3毫^/售屬布萊傑.目利之子實體抽出 微克/隻)之混合物、於史隻私)與乳酸球菌加熱處理菌體(10 體(20微克/隻)、於比較群較9群丨投予/L酸球菌加熱處理菌 、 較群2投予松蕈屬·布萊傑.目利之 子實體抽出物(乾燥子實體〇. 6毫克/隻)、⑨對照群投予磷 酉夂緩衝鹽水(phosphsate buffer saline' PBS)(0 2 毫升/ 隻)投予1週。 | 然後,於老鼠腹腔内注射李斯特菌(Listeria monocytogenes )使成2x 10 5CFU/隻後,觀察各群老鼠之 生存率。又’於試驗期間自由攝取水及飼料(商品名「粉 末飼料CE-2」、日本克雷亞公司製造)。 該結果如第1圖所示,於第1圖,試驗群、比較群1、》 與對照群相比,顯示非常高之生存率。尤其是於試驗群之 老鼠,連1隻都沒有死亡,明瞭李斯特菌之感染·增殖被 抑制。 置例2_ 與實施例1相同操作,從試驗開始1週前起,每日j次 於各群之老鼠強制經口投予試驗試樣,使感染李斯特菌。
1230611 五、發明說明(9) 然後採取老鼠之脾臟’測定脾臟所感染李斯特菌數之變 化。具體而言’感染後於苐1、3、5、7曰採取脾臟,將該 脾臟磨碎’懸濁於填酸緩衝鹽水中’將該懸濁液階段式稀 釋,移至「李斯特增邊培養基」(商品名、默克公司製 造)、培養(2 5°C、48小時),测定所出現之菌群體數,該 結果如第2圖所示。 由第2圖明瞭從感染後第3日起,於對照群,李斯特菌 數增加,相對地,於試驗群、比較群1、2則減少。尤其是 於試驗群,該減少之比例較大。
由該等結果明暸,將松蕈屬·布萊傑·目利之子實體 抽出物與乳酸球菌加熱處理菌體併用,經口攝取比各自單 獨攝取時顯示優越之感染抑制效果。 經由 體抽出物 抑制效果 下述之方法研究將松簟屬·布萊傑·目利之子實 與乳酸球菌加熱處理菌體併用,經口攝取,感染 之作用機序。 ^ 1 ) C D 3陽性α点型T細胞之表面抗原解析 了、於檢疫·驗收完成後將已飼育1週之BALB/C老鼠(雌、 I週歲、購自曰本查爾滋利巴(股)公司)分成2群(每群3 用胃管每群每日1次連續經口投予,於試驗群投予松 蕈凰 * /隹15 ·布萊傑·目利之子實體抽出物(乾燥子實體0·2毫克 )與乳酸球菌加熱處理菌體(2 〇微克/隻)之混合物(〇 _ 2 =升/隻)、於對照群投予磷酸緩衝鹽水(0 · 2毫升/隻)1週 從老鼠尾靜脈注射李斯特菌(Listeria
1230611 五、發明說明(10) monocytogenes )使成14χ i〇4CFlj/隻。又,於飼養期間 自由攝取水及飼料(商品名「粉末飼料CE-2」、日本克雷 亞公司製造)。 於接種李斯特菌後第5日將各群之老鼠屠殺,採取腸 管膜淋巴結。將該腸管膜淋巴結用毛玻璃夾住,懸濁於含 有10%FBS之RPMI-1640培養液(商品名、姻厝晉 (Introgen)公司製造)、洗淨,用不銹鋼篩子除去多餘之 組織片,分別調製試驗群及對照群之腸管膜淋巴結細胞 (以下稱為MLN)。 將各MLN懸濁於含有i〇%FBS之RPMI-1640培養液中, 使成5x 10 5個/毫升,於6個洞之培養盤(可寧克斯塔 (Corning Co star )公司製造)之每個洞注入1毫升。又, 於每個洞加入經絲裂霉素C(mi tomycin C)處理過、未處理 過之來自8人18/(:老鼠之脾細胞(5父105個)及李斯特菌加熱 死菌體(1· Ox 106CFU)混合作為刺激劑(Stimulator),於 37 °C、5%二氧化碳存在下培養48小時。上述未處理之老 鼠為未投予被驗物質及未進行菌接種之老鼠。 將各MLN用下述3種類之標識抗體(所有抗體均購自貝 克頓迪克森法敏公司(Becton Dickinson PharMingen)) 染色,進行細胞表面抗原之解析。 0〇丫-〇:1^〇111(〇7)標識抗003£111八1)/^1丁(:標識抗1^1^;3 mAb/PE標識抗CD4mAb /生物素(biotin)標識抗CD8mAb ②Cy標識抗CD3 ε mAb/FITC標識抗TCR a /5 mAb/PE標識 抗〔0 6 911^1)/生物素標識抗[0811^乜
313641.ptd 第14頁 1230611 五、發明說明(11) ③Cy標識抗CD3 ε mAb/F ITC標識抗TCR α Θ niAb/PE標識 抗CD 12 2mAb/生物素標識抗CD8mAb 亦即,於調製成1_ Ox l〇5個之MLN浮游液申添加上述 ①所示之標識抗體5微升,於4°C保溫45分鐘後用含有5% FBS之漢克(Hank’s)緩衝液洗淨2次,加入莎紅613(SA-RED 613)(商品名、姻厝晉公司製造)5微升,於4它保溫45分鐘 後用含有5% FBS之漢克(Hank,s)緩衝液洗淨3次。經由流 動細胞計算器(型式「Epics XL」、貝克曼卡特公司 (Beckman Coulter Inc·)製造)解析MLN之表面抗原,求 CD4—CD8+對於CD4+CD8-之比率,比較CD8陽性率。該結果如 表2所示。 【表2】 對於CD3 + α /3 TCR+細胞總數之% MLN(mean土 SD) 比率(Β/Α) CD4 + CD8-(A) CD4-CD8 + (B) 對照群 29.1+ 1.3 26.4土 1·2 0·9± 0.3 試驗群 20·4± 1·2 43·7± 1·2 2·1± 0·3 由表2明瞭,試驗群之CD8陽性率與對照群相比較為約 2倍高’經由攝取松蕈屬·布萊傑·目利之子實體抽出物 及乳酸球菌加熱處理菌體,CD8陽性率變高。 又’以CD69(初期活性標識器)及CD 122(1 L-2接受體/3 鏈)作為指標,檢討CD8陽性τ細胞有無活性化。亦即使用 上述②、③所示之標識抗體,依照與上述相同之方法解析 細胞之表面抗原。該結果如表3所示。
313641.ptd
第15頁 1230611 五、發明說明(12) 【表3】 對於0〇3+«々1^11+〇〇8 +細胞總數之% MLN(mean土 SD) CD69 + CD122 + 對照群 38.6 土 1.2 35.5土 1.8 試驗群 42.2± 1.2 43.8士 1.4 由表3明瞭,試驗群之CD69及CD122之陽性率比對照群 高,經由攝取松蕈屬·布萊傑·目利之子實體抽出物及乳 酸球菌加熱處理菌體,促進CD8陽性T細胞活性化。 (2)細胞漿(cytokin)產生量 與上述同樣操作,調製對照群及試驗群之MLN,加入 刺激劑,於37°C、在5%二氧化碳存在下培養48小時。 培養完成後回收培養液上層澄清液,用ELISA法測定 培養液上層澄清液中之細胞漿量(IL-2、IL-10、IL-12、 IFN-7 )。又,使用購自姻得晉(Endogen)公司之測定工具 測定IL-2、IL-12、IFN-τ ,使用購自安氏阿札科技公司 (AN’ ALYZA TECHNE Co_,)之測定工具測定IL-1 0。該結果 如第3圖所示。 由第3圖明瞭,於試驗群,τ helper l(Th-l)型細胞 漿之IFN_r及IL-12之產生量非常高,T helper 2(Th-2) 型細胞漿之IL-10之產生量非常低。 又,經由RT-PCR法研究細胞漿特異性mRNA之發現量時 明瞭,於試驗群,Th-Ι型細胞漿之IL-12、IFN-γ及TNF-α之mRNA顯現量增強。另一方面,Th-2型細胞漿之IL-10
313641.ptd 第16頁 1230611 五、發明說明(13) 之mRNA顯現量無差異。 已知,於感染李斯特菌等細胞内寄生細菌之生體内, 巨噬細胞或NK細胞被活化,各自產生IL-12及IFN-T該等 細胞漿更能使細菌抗原特異性CD8陽性T細胞活化,該結果 可經由具有細胞障礙活性(CTL)之CD8陽性T細胞將菌排 除。又,經由T細胞產生之TNF-α具有將嗜中性白血球或 巨噬細胞等食細胞集合在感染之局部地方之作用。 亦即,由上述之各結果認為,將松蕈屬.布萊傑.目 利之子實體抽出物及乳酸球菌併用、投予,更促進巨嘆細 胞或NK細胞之活化,IL-12及IFN-r等之產生量增大之結 果亦促進李斯特菌特異性CD8陽性細胞活化,菌之排除比 對照群更快。 【發明之效果】 如以上之說明’根據本發明,可提供以含有松蕈屬· 布萊傑·目利之子實體及/或菌絲體培養物之抽出物及乳 酸菌之加熱處理菌體作為有效成分之具有優越感染抑制效 果之組成物。又,經由將本發明之感染抑制組成物添加於 飲食品,可提供可預防病原菌等感染之飲食品。 、 本發明之感染抑制組成物係來自食品,安全性高,經 由攝取該組成物,可促進以細胞性免疫為中心之生體防〶 機構活性化,可期待預防病原菌等之感染之效果。 w
1230611 圖式簡單說明 【圖表之簡單說明】 【第1圖】為表示感染李斯特菌後老鼠生存率之圖 表。 【第2圖】為表示於感染李斯特菌之老鼠脾臟中李斯 特菌數測定結果之圖表。 【第3圖】為用ELISA法測定腸管膜淋巴結細胞(MLN) 培養液上層澄清液中細胞漿量(IL-2、IL-10、IL-12、 IFN-7 )之結果之圖表。
313641.ptd 第18頁
Claims (1)
- 0 :^无 §a iL — 5 _號 91110088_M 年/ / 月 Γ a__ 六、申請ϊ利範s 1. 一種感染抑制組成物,其特徵為:含有松蕈屬·布萊 傑·目利(Agaricus blazei Murill)之子實體及/或菌 絲體培養物之抽出物及乳酸菌之加熱處理菌體作為有 效成分。 2·如申請專利範圍第1項之感染抑制組成物,其中,該上 述乳酸菌係為乳酸球菌(E n t e r 〇 c 〇 c c u s f a e c a 1 i s )者。 3. 如申請專利範圍第1項或第2項之感染抑制組成物,其 中,該組成物係含有上述松蕈屬·布萊傑·目利 (Agaricus blazei Murill )之子實體及/或菌絲體培養 物之抽出物0 . 5至9 9. 5質量%、上述乳酸菌之加熱處理 菌體99. 5至0. 5質量%者。 4. 一種食品組成物,其特徵為:含有如申請專利範圍第1 項至第3項任何一項之感染抑制組成物。 5. 如申請專利範圍第4項之食品組成物,其中,該食品組 成物之每回攝取量係含有上述感染抑制組成物0. 0 1至 1 0公克者。313641 修正本.ptc 第19頁
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001150643 | 2001-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI230611B true TWI230611B (en) | 2005-04-11 |
Family
ID=18995629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW091110088A TWI230611B (en) | 2001-05-21 | 2002-05-15 | Anti-infection composition and food containing such anti-infection composition |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR20020089149A (zh) |
CN (1) | CN1269490C (zh) |
SG (1) | SG93936A1 (zh) |
TW (1) | TWI230611B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110234331B (zh) * | 2017-01-30 | 2023-06-16 | 营养株式会社 | Mrsa感染保护剂 |
AU2019214149A1 (en) * | 2018-01-31 | 2020-07-09 | Nutri Co., Ltd. | Prophylactic and/or therapeutic agent for pneumococcal infection |
US20200405784A1 (en) * | 2018-04-19 | 2020-12-31 | Nutri Co., Ltd. | Agent for Prevention and/or Treatment of Pseudomonas Aeruginosa Infection |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5157858A (en) * | 1974-11-15 | 1976-05-20 | Shigenobu Watari | Nyusankininryono seizohoho |
US4110477A (en) * | 1977-05-13 | 1978-08-29 | Kabushiki Kaisha Naruse Fermentation Laboratory | Method for producing natto containing lactic acid bacteria |
KR19980075714A (ko) * | 1997-04-01 | 1998-11-16 | 김용구 | 아가리쿠스버섯 함유 건강음료 제조방법 |
JPH11113531A (ja) * | 1997-10-17 | 1999-04-27 | Hudson Shoji Kk | 健康食品 |
JPH11130690A (ja) * | 1997-10-29 | 1999-05-18 | Miyato Higaki | 免疫調節薬及び抗炎症薬 |
KR19990046012A (ko) * | 1999-03-10 | 1999-06-25 | 조성인 | 상황버섯또는신령버섯균사체를이용한차및음료의제조방법 |
JP3627968B2 (ja) * | 1999-11-04 | 2005-03-09 | 株式会社応微研 | 乳酸発酵食品およびその製造方法 |
-
2002
- 2002-05-03 SG SG200202671A patent/SG93936A1/en unknown
- 2002-05-15 TW TW091110088A patent/TWI230611B/zh not_active IP Right Cessation
- 2002-05-16 KR KR1020020027056A patent/KR20020089149A/ko not_active Application Discontinuation
- 2002-05-21 CN CNB02121607XA patent/CN1269490C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1386510A (zh) | 2002-12-25 |
KR20020089149A (ko) | 2002-11-29 |
CN1269490C (zh) | 2006-08-16 |
SG93936A1 (en) | 2003-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4521687B2 (ja) | プロバイオティクス、プロピオニバクテリウム・イエンセニー702 | |
US11268064B2 (en) | Lactobacillus rhamnosus RHT-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases | |
WO2013099883A1 (ja) | IgA産生促進作用を有する新規乳酸菌及びその用途 | |
CN102665740A (zh) | 组合物和方法以及与其相关的用途 | |
RU2415920C2 (ru) | Применение специфических молочнокислых бактерий для получения композиции, пригодной для стимуляции иммунного ответа при заболеваниях, связанных с изменениями в иммунной системе | |
US20100143303A1 (en) | Composition comprising lactic acid bacterium having high anti-allergic activity, and method for production of the lactic acid bacterium | |
TW200538047A (en) | A composition having immunoregulating activities | |
KR20180054029A (ko) | 웨이셀라 시바리아로부터 유래한 세포외 다당류를 포함하는 면역력 증강을 위한 조성물 | |
JP2010202557A (ja) | Nk活性増強剤 | |
JP2005220065A (ja) | 免疫賦活剤 | |
JP6796299B2 (ja) | 免疫賦活用組成物及びサイトカイン産生促進用組成物 | |
JP4499979B2 (ja) | 病原菌感染抑制用組成物 | |
JP6261688B2 (ja) | Qol改善又は持続剤 | |
TW201609120A (zh) | 含乳酸菌之腸道屏障功能促進劑 | |
TWI230611B (en) | Anti-infection composition and food containing such anti-infection composition | |
WO2020067422A1 (ja) | T細胞を活性化するための組成物 | |
KR20180083841A (ko) | 베타글루칸 및 항결핵제를 유효성분으로 포함하는, 결핵 예방 및 치료용 약학적 조성물 | |
WO2017022560A1 (ja) | 形質細胞様樹状細胞増加剤 | |
EP2486931B1 (en) | Therapeutic agent for influenza virus infectious diseases | |
KR102485269B1 (ko) | 비피도박테리움 비피덤을 포함하는 면역력 증강 또는 개선용 조성물 | |
KR20190129322A (ko) | 나노화된 김치 유산균을 함유하는 항바이러스용 약학조성물 | |
JP2019131475A (ja) | がん転移抑制剤 | |
WO2023120547A1 (ja) | 二次性感染症の予防又は発症リスクを低減するための組成物 | |
JP6529835B2 (ja) | 樹状細胞活性化剤 | |
KR20230064833A (ko) | 면역기능 개선 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |